艾曲波帕 (Eltrombopag, olamine) 25mg
1. Composition:
The active ingredient of Eltrombopag is Eltrombopag itself, with the chemical name N-(1-fluoro-4-pyridinyl)-3-methyl-4-(2-amino-4-thiazolyl)benzene sulfonamide. Its molecular formula is C25H30F3N3O4S, and the molecular weight is 477.6 g/mol.
2. Pharmacological Effects:
Eltrombopag increases platelet counts by stimulating platelet production and increasing the number of megakaryocytes in the bone marrow. Its indications include:
- Chronic Immune Thrombocytopenic Purpura (ITP): Increases platelet counts and reduces the risk of bleeding.
- Liver Disease-related Thrombocytopenia: Improves platelet counts and reduces the risk of bleeding during surgeries and other invasive procedures.
- Chemotherapy-related Thrombocytopenia: Reduces thrombocytopenia caused by chemotherapy.
3. Dosage and Administration:
Eltrombopag is usually administered in oral tablet form, with a recommended dosage of 25 mg per day. The specific dosage can be adjusted based on the patient’s condition and platelet count. It should be used under medical supervision, with regular monitoring of platelet levels and liver function.
4. Research and Development History:
Eltrombopag was developed by GlaxoSmithKline (GSK) and received FDA approval in 2008 for the treatment of chronic immune thrombocytopenic purpura. Its development aimed to provide new treatment options for patients with refractory thrombocytopenia, especially those unresponsive to other treatments.
5. Mechanism of Action:
Eltrombopag is a small-molecule thrombopoiesis stimulator that primarily promotes the proliferation and maturation of megakaryocytes by activating the thrombopoietin receptor (TPO receptor). This drug mimics endogenous thrombopoietin, stimulating megakaryocytes in the bone marrow to produce more platelets. Through this mechanism, Eltrombopag effectively increases platelet counts, thereby reducing the risk of bleeding.
6. Summary :
Eltrombopag is an effective medication for treating thrombocytopenia, particularly suitable for chronic immune thrombocytopenic purpura and liver disease-related thrombocytopenia. It stimulates platelet production, increases platelet counts, reduces bleeding risks, and improves patients' quality of life.
